Association between high-risk disease loci and response to anti-vascular endothelial growth factor treatment for wet age-related macular degeneration.
about
Resistance to antivascular endothelial growth factor treatment in age-related macular degenerationGenetic risk, ethnic variations and pharmacogenetic biomarkers in age-related macular degeneration and polypoidal choroidal vasculopathyAssociation between polymorphism rs11200638 in the HTRA1 gene and the response to anti-VEGF treatment of exudative AMD: a meta-analysis.Association between variant Y402H in age-related macular degeneration (AMD) susceptibility gene CFH and treatment response of AMD: a meta-analysis.Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT)No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38Pharmacogenetic associations with long-term response to anti-vascular endothelial growth factor treatment in neovascular AMD patientsSuggestive association between PLA2G12A single nucleotide polymorphism rs2285714 and response to anti-vascular endothelial growth factor therapy in patients with exudative age-related macular degeneration.Genetic studies of age-related macular degeneration: lessons, challenges, and opportunities for disease management.Pharmacogenetic association with early response to intravitreal ranibizumab for age-related macular degeneration in a Korean populationPredictors of visual response to intravitreal bevacizumab for treatment of neovascular age-related macular degenerationInfluence of CFH, HTRA1 and ARMS2 polymorphisms in the response to intravitreal ranibizumab treatment for wet age-related macular degeneration in a Spanish population.Pharmacogenetics of the treatment response of age-related macular degeneration with ranibizumab and bevacizumab.Association between variants A69S in ARMS2 gene and response to treatment of exudative AMD: a meta-analysis.Identifying Common Genetic Risk Factors of Diabetic Neuropathies.Association of the polymorphism Y402H in the CFH gene with response to anti-VEGF treatment in age-related macular degeneration: a systematic review and meta-analysis.Risk factors and biomarkers of age-related macular degeneration.A prospective multicenter study on genome wide associations to ranibizumab treatment outcome for age-related macular degeneration.Pharmacogenetics of Complement Factor H Y402H Polymorphism and Treatment of Neovascular AMD with Anti-VEGF Agents: A Meta-Analysis.Incidence and risk factors of retreatment after three-monthly aflibercept therapy for exudative age-related macular degeneration.ARMS2 A69S polymorphism is associated with the number of ranibizumab injections needed for exudative age-related macular degeneration in a pro re nata regimen during 4 years of follow-up.Pharmacogenetic labyrinth of neovascular age-related macular degeneration therapy: how to escape and move forward?Association of genetic polymorphisms with response to bevacizumab for neovascular age-related macular degeneration in the Chinese population.Exploring the Use of Molecular Biomarkers for Precision Medicine in Age-Related Macular Degeneration.
P2860
Q27015781-DFE325DC-D362-438E-8C0C-C26A7DFC501FQ33645265-83D67E66-EEEA-4335-B3BA-ACAF30522F49Q33823849-75CCE4F3-C7B5-44F7-B3FC-4975A2E040A8Q34384420-2BE63240-42D8-4FF5-BA6B-F60DD495A149Q34556444-FEA50082-16B7-4777-9A8E-B261FAC279A0Q34620551-C7A4DCB1-C7CF-4CE7-AFDB-0B6D78BB8651Q34781693-88722293-7D25-4305-90C9-FC139C795050Q36350410-8AF6C8A2-2619-456D-B038-6EEF450C972CQ36445951-EE8E6B32-9ACE-4ED9-A2AB-0FDD9ACD711BQ36727716-22B1EFF2-6C1A-462E-A91F-35622C280B33Q37166529-86530CAF-D9EA-426A-B7C5-26DCB77B241BQ37266897-E13DF134-C0F4-4DDA-928C-F0865BCA38C0Q38134807-2452879D-9A0A-4D8C-A302-329D16F70887Q38245807-F8061C28-0400-4A73-8E45-F35768D5794CQ38527798-3952D9EF-FD91-47AC-A201-7256FF07ECC3Q38827325-E658D2C7-F7D1-4C73-81A4-215BF8377087Q38828895-38D92F47-26F9-40F5-AB5A-AA7DEA659822Q41504310-E71BE013-B796-4A81-8AD6-F513CDBF4E8DQ41833477-7B855184-1D89-4103-862E-5951E6653BA8Q42136459-595D5D56-6639-4E4B-A95A-6B191DE2FC05Q43364243-35AD4FF8-8379-44F1-A6E7-9EF8FA1D82E6Q44097181-C9128849-D215-4B42-BEB4-4111DEECEFF8Q49176127-38F07DF5-EDFF-4FAA-A75F-D54834075DA0Q52559837-E0D45EF1-9CF0-4B0E-BB3C-F413E5E68482
P2860
Association between high-risk disease loci and response to anti-vascular endothelial growth factor treatment for wet age-related macular degeneration.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Association between high-risk ...... -related macular degeneration.
@en
Association between high-risk ...... -related macular degeneration.
@nl
type
label
Association between high-risk ...... -related macular degeneration.
@en
Association between high-risk ...... -related macular degeneration.
@nl
prefLabel
Association between high-risk ...... -related macular degeneration.
@en
Association between high-risk ...... -related macular degeneration.
@nl
P2093
P1433
P1476
Association between high-risk ...... -related macular degeneration.
@en
P2093
Allen C Ho
Anton Orlin
Ashlee N Godshalk
Audun Lier
Brian Kaderli
Carl D Regillo
Gary Brown
Richard S Kaiser
Woohyok Chang
P356
10.1097/IAE.0B013E31822A2C7C
P577
2012-01-01T00:00:00Z